Vemurafenib Completed Phase 1 Trials for Malignant Melanoma, Cancer Basic Science

IndicationsStatusPurposePhase
CompletedBasic Science1
clinicaltrials.gov IdentifierTitleDrugs
NCT02441465Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive Malignancies